Protocol for PTEN Expression by Immunohistochemistry in Formalin-fixed Paraffin-embedded Human Breast Carcinoma

Overview

Journal Appl Immunohistochem Mol Morphol

Specialties Biochemistry
Cell Biology
Molecular Biology

Date 2010 Mar 11

PMID 20216404

Citations 37

Authors

Rita A Sakr

Violetta Barbashina

Mary Morrogh

Sarat Chandarlapaty

Victor P Andrade

Crispinita D Arroyo

Narciso Olvera

Tari A King

Affiliations

Soon will be listed here.

Abstract

The PI3K/PTEN pathway plays a major role in carcinogenesis. Dysregulation of this pathway occurs frequently in breast cancer, and loss of PTEN expression is emerging as a potentially important mechanism of resistance to the widely used anti-HER2 therapy, trastuzumab. However, assays for loss of PTEN expression have suffered from lack of consistency. Here, we describe an automated and reliable protocol for PTEN protein expression by immunohistochemistry in formalin-fixed paraffin-embedded tissue that can be easily incorporated into clinical trials.

Citing Articles

INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomas.

Elbatsh A, Amin-Mansour A, Haberkorn A, Textor C, Ebel N, Renard E Nat Cancer. 2024; 5(3):481-499.

PMID: 38233483 PMC: 10965444. DOI: 10.1038/s43018-023-00710-z.

Inhibition of ubiquitin specific peptidase 8 is effective against 5-fluorouracil resistance in colon cancer via suppressing EGFR and EGFR-mediated signaling pathways.

Xi C, Gong Z, Ye H, Cao L, Yu J Histol Histopathol. 2023; 39(2):251-261.

PMID: 37222451 DOI: 10.14670/HH-18-629.

The impact of PIK3CA mutations and PTEN expression on the effect of neoadjuvant therapy for postmenopausal luminal breast cancer patients.

Hayama S, Nakamura R, Ishige T, Sangai T, Sakakibara M, Fujimoto H BMC Cancer. 2023; 23(1):384.

PMID: 37106324 PMC: 10134571. DOI: 10.1186/s12885-023-10853-y.

Reducing N6AMT1-mediated 6mA DNA modification promotes breast tumor progression via transcriptional repressing cell cycle inhibitors.

Chen J, Zhuang Y, Wang P, Ning J, Liu W, Huang Y Cell Death Dis. 2022; 13(3):216.

PMID: 35256595 PMC: 8901905. DOI: 10.1038/s41419-022-04661-8.

The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted Therapy.

Saigusa N, Hirai H, Tada Y, Kawakita D, Nakaguro M, Tsukahara K Front Oncol. 2022; 11:779882.

PMID: 35186711 PMC: 8850643. DOI: 10.3389/fonc.2021.779882.

References

Lee J, Soria J, Hassan K, El-Naggar A, Tang X, Liu D . Loss of PTEN expression as a prognostic marker for tongue cancer. Arch Otolaryngol Head Neck Surg. 2001; 127(12):1441-5. DOI: 10.1001/archotol.127.12.1441. View

Bose S, Crane A, Hibshoosh H, Mansukhani M, Sandweis L, Parsons R . Reduced expression of PTEN correlates with breast cancer progression. Hum Pathol. 2002; 33(4):405-9. DOI: 10.1053/hupa.2002.124721. View

Parsons R . Human cancer, PTEN and the PI-3 kinase pathway. Semin Cell Dev Biol. 2004; 15(2):171-6. DOI: 10.1016/j.semcdb.2003.12.021. View

Garcia J, Silva J, Pena C, Garcia V, Rodriguez R, Cruz M . Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosomes Cancer. 2004; 41(2):117-24. DOI: 10.1002/gcc.20062. View

Nagata Y, Lan K, Zhou X, Tan M, Esteva F, Sahin A . PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004; 6(2):117-27. DOI: 10.1016/j.ccr.2004.06.022. View

Faratian D, Goltsov A, Lebedeva G, Sorokin A, Moodie S, Mullen P . Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab. Cancer Res. 2009; 69(16):6713-20. DOI: 10.1158/0008-5472.CAN-09-0777. View

Steck P, Pershouse M, Jasser S, Yung W, Lin H, Ligon A . Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997; 15(4):356-62. DOI: 10.1038/ng0497-356. View

Rhei E, Kang L, Bogomolniy F, Federici M, Borgen P, Boyd J . Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res. 1997; 57(17):3657-9. View

Perren A, Weng L, Boag A, Ziebold U, Thakore K, Dahia P . Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol. 1999; 155(4):1253-60. PMC: 1867038. DOI: 10.1016/S0002-9440(10)65227-3. View

10.

Thomas G, Horvath S, Smith B, Crosby K, Lebel L, Schrage M . Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer. Clin Cancer Res. 2004; 10(24):8351-6. DOI: 10.1158/1078-0432.CCR-04-0130. View

11.

Tsutsui S, Inoue H, Yasuda K, Suzuki K, Higashi H, Era S . Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast. Oncology. 2005; 68(4-6):398-404. DOI: 10.1159/000086981. View

12.

Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang S . PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997; 275(5308):1943-7. DOI: 10.1126/science.275.5308.1943. View